Dr. Jessica McDaniel successfully defended her dissertation on August 24, 2012 and is pictured here with her committee. From left to right: Committee members Javier Pinilla-Ibarz and Sheng Wei; Dissertation Chair Neal Young, NIH; Jessica McDaniel; Major Professor P.K. Burnette; committee members Julie Djeu and Xue-Zhong Yu. Dr. McDaniel initially joined the Office of Technology Commercialization and Knowledge Transfer at Ohio State University as a postdoctoral licensing analyst. She is now a Senior MSL with Celgene.
Dr. McDaniel's publications while in the program:
McDaniel JM, Zou JX, Fulp W, Chen DT, List AF, Epling-Burnette PK.Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation.Leukemia. 2011 Dec 23. doi: 10.1038/leu.2011.359.
McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. 2012, Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol. July 2012:513702
Dr. McDaniel's publications since graduation:
Epling-Burnette PK, McDaniel J, Wei S, List AF. Emerging immunosuppressive drugs in myelodysplastic syndromes. Expert Opin Emerg Drugs. 2012 Dec;17(4):519-41. doi: 10.1517/14728214.2012.736487. Epub 2012 Nov 20. Review. PMID: 23163589
Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Jun 20;121(25):5068-77. doi: 10.1182/blood-2012-10-460170. Epub 2013 Apr 30. PMID: 23632888